摘要
目的 分析晚期食管鳞癌患者采用卡瑞利珠单抗联合安罗替尼治疗的临床效果.方法 将65例晚期食管鳞癌患者随机分为对照组(n=32)及观察组(n=33).对照组采用替吉奥联合安罗替尼治疗,观察组采用卡瑞利珠单抗联合安罗替尼治疗,21 d为1个疗程,均连续治疗4个疗程.治疗结束后评估2组患者近期疗效、血清肿瘤标志物水平、免疫功能及不良反应发生情况.结果 观察组疾病控制率(84.85％)显著高于对照组(59.38％)(P＜0.05).治疗后2组患者血清癌胚抗原(CEA)、糖抗原19-9(CA19-9)、糖抗原125(CA125)及鳞状上皮细胞癌抗原(SCC)表达下降;且观察组水平显著低于对照组(P＜0.001).治疗后2组患者CD3+、CD4+及CD4+/CD8+水平上升,CD8+水平下降;且观察组水平变化与对照组相比更为显著(P＜0.01).2组患者高血压、转氨酶升高、食欲下降、乏力及毛细血管增生症发生率差异无统计学意义(P＞0.05);观察组患者粒细胞下降及血小板下降发生率低于对照组患者,且差异具有统计学意义(P＜0.01).结论 卡瑞利珠单抗联合安罗替尼可显著降低血清肿瘤标志物水平,改善患者免疫功能,提高临床疗效,且安全性较高,值得临床推广.
Abstract
Objective To analyze the clinical effect of carrilizumab combined with anrotinib in patients with advanced e-sophageal squamous cell carcinoma.Methods A total of 65 patients with advanced esophageal squamous cell carcinoma were randomly divided into the control group(n=32)and the observation group(n=33).The control group was treated with tegafur combined with anrotinib for 21 days as a course of treatment,and the observation group was treated with carrilizumab combined with anrotinib for 21 days as a course of treatment,and both groups were treated for 4 consecutive courses of treatment.After treat-ment,the short-term efficacy,serum tumor marker levels,immune function,and the occurrence of adverse reactions were evaluated in both groups.Results The disease control rate of observation group(84.85％)was significantly enhanced compared with con-trol group(59.38％)(P＜0.05).After treatment,the expression of serum CEA,CA19-9,CA125,and SCC levels in 2 groups were decreased,and the levels of the above indexes in the observation group were significantly lower than those in the control group(P＜0.001).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+were increased,while the level of CD8+was decreased,and the changes of the above indexes in the observation group were more significant than those in the control group(P＜0.01).There was no statistical significance in the incidence of hypertension,elevated transaminase,decreased appetite,fatigue,and capil-lary hyperplasia between 2 groups(P＞0.05).The incidences of granulocytopenia and thrombocytopenia in observation group were significantly declined compared with control group(P＜0.01).Conclusion Carrellizumab combined with anrotinib could signifi-cantly reduce the level of serum tumor markers,improve the immune function of patients,and improve clinical efficacy with high safety,which is worthy of clinical promotion.
维普
万方数据